Premium
Necrolytic migratory erythema: a classical cutaneous presentation of the glucagonoma syndrome
Author(s) -
Jones S.A. Vaughan,
Dunnill M.G.S.,
Wilding J.,
Liddell K.,
Gorsuch A.N.,
Bloom S.R.,
Black M.M.
Publication year - 1997
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.1997.tb00231.x
Subject(s) - glucagonoma , medicine , dermatology , presentation (obstetrics) , lanreotide , differential diagnosis , erythema , pathology , surgery , glucagon , insulin , acromegaly , growth hormone , hormone
We report a case of necrolytic migratory erythema secondary to an underlying pancreatic glucagonoma causing the glucagonoma syndrome. We discuss the differential diagnosis of necrolytic migratory erythema and the importance of recognising this rare endocrine tumour with its marked cutaneous features. Patients with glucagonoma syndrome can present late in a debilitated suite and often require much nutritional support. Treatment with a new long‐acting somatostatin analogue, Lanreotide (Somatuline S.R.) 30 mg once weekly, has in our case so far produced encouraging results. We would like to emphasise the importance of the insidious onset of this syndrome and the high incidence of metastatic disease at presentation.